Ibandronate Sodium(eh ban’ drow nate)
BonivaDNC
PREGNANCY CATEGORY C
Drug Classes
Bisphosphonate
Calcium regulator
Therapeutic Actions
Inhibits osteoclast activity and reduces bone resorption and turnover, without inhibiting bone formation or mineralization.
Indications
Treatment and prevention of osteoporosis in postmenopausal women
Unlabeled uses: Treatment of metastatic bone disease in breast cancer, treatment of hypercalcemia of malignancy, treatment of multiple myeloma
Contraindications and Cautions
Contraindicated with known allergy to any component of the tablet, uncorrected hypocalcemia, inability to stand or sit upright for at least 60 minutes (oral form).
Use caution with known upper GI abnormalities, pregnancy, lactation.
Available Forms
Prefilled syringe—1 mg/mL; tabletsDNC—150 mg
Dosages
Adults
One 150-mg tablet PO once/mo on the same date each mo, or 3 mg IV given over 15–30 sec, every 3 mo.
Pediatric patients
Safety and efficacy not established.
For patients with renal impairment
Not recommended with severe renal impairment (CrCl less than 30 mL/min).
Pharmacokinetics
|
Metabolism: T1/2: 37–157 hr (oral); 5–25 hr (IV)
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
